Teva Pharmaceuticals Names New EVP of Global Operations

Teva Pharmaceutical Industries has appointed Matthew Shields as executive vice president of Teva Global Operations (TGO), the company’s manufacturing and supply division, effective June 3, 2024.

Shields succeeds Eric Drapé, who is leaving after 11 years with Teva Pharmaceuticals, including more than four years in the EVP role. Shields will be a member of Teva’s Executive Leadership Team and be based at Teva’s US headquarters in Parsippany, NJ.

“I’m thrilled to welcome a transformational leader of Matthew’s caliber to the executive team at Teva,” said Richard Francis, Teva's president and CEO. “Matthew brings a wealth of experience in health operations that are critical to fulfilling our purpose by enabling Teva to execute on our promises to patients and healthcare systems around the world. Matthew is ideally positioned to lead our TGO organization through the next phase of our Pivot to Growth journey.”

With more than 25 years in the global biopharmaceutical and animal health industries and an engineer by trade, Shields brings significant experience at every stage of the manufacturing and supply process. Most recently, he was senior vice president for Animal Health Manufacturing for Merck, where he oversaw end-to-end manufacturing, supply chain, procurement, and process development. Prior to Merck, he led Specialty Care Manufacturing, Engineering, and Operational Excellence for Sanofi. Shields spent much of his early career at Amgen, where held a variety of leadership roles in Operations.